



GRADUATE CERTIFICATE IN PHARMACEUTICAL REGULATION

GMS5003: Fundamentals of Health Products Regulation

9 September 2024 – 13 September 2024

Venue: White Space Room (Level 2), Academia, 20 College Road, Singapore 169856

WORKSHOP PROGRAMME

Learning outcomes

- Explain the foundational basis of regulatory management and decision-making for health products
- Explain the essential principles in managing pharmaceuticals across their life cycles
- Describe the regulatory requirements for the different product development phases
- Relate to the real-life settings in regulatory decision-making through hands-on practical sessions
- Recognize the major regulatory organisations steering the innovation of regulatory processes and focus

Graduate Certificate in Pharmaceutical Regulation

GMS5003: Fundamentals of Health Products Regulation

9 September 2024 – 13 September 2024

Day 1 – 9 September 2024, Mon

| Topic | Speaker/ Organisation |
|--|---|
| 8.30 am Welcome Graduate Certificate Students | Professor John C W Lim Executive Director CoRE Duke-NUS Medical School |
| 9.00 am Workshop Briefing | Dr Rathi Saravanan Lead Education Associate Centre of Regulatory Excellence (CoRE) Duke-NUS Medical School |
| 9.15 am Brightspace and Assessment Familiarization | Mr. Osman Bin Mohamad Senior Education Associate Centre of Regulatory Excellence (CoRE) Duke-NUS Medical School |
| 9.30 am Pre-workshop Assessment | CoRE Education Team |
| Session 1: Health Products Regulatory Overview and Role of Regulatory Professionals | |
| 9.45 am Introduction to pharmaceutical regulation in the context of healthcare in resource endowed and resource constrained settings <ul style="list-style-type: none"> Provide broad overview of how regulations are evolving in the context of changing global landscape | Dr Murray Lumpkin Deputy Director – Integrated Development Lead, Global Regulatory Systems Initiatives Bill and Melinda Gates Foundation, US |
| 11.00 am Refreshment Break | |
| 11.30 am To understand the role of regulation – and different approaches to regulation – in each phase of the product lifecycle <ul style="list-style-type: none"> The role of pharmaceutical regulations and its contribution to the healthcare environment | Dr Charles Preston Senior Program Officer Bill & Melinda Gates Foundation, US |
| 12.30 pm Lunch | |
| 1.30 pm Role of regulatory professionals <ul style="list-style-type: none"> Role of regulatory professionals Professional development frameworks | Mr Thean Soo (TS) LO Regulatory Affairs Management Consultant TS Consulting |
| 2.15 pm Health Products Regulation: Role of stakeholder interactions for effective regulatory decision making <ul style="list-style-type: none"> Pre-consultations in guiding development Importance of stakeholder interactions in ensuring SEQ of pharmaceutical products | Mr Thean Soo (TS) LO TS Consulting |
| 3.00 pm Refreshment Break | |
| Session 2: Health Products Development Overview and Commercialisation Strategies | |
| 3.15 pm Target Product Profiling (TPP) in product development <ul style="list-style-type: none"> Use of TPP significance in product development and market entry | Dr Deborah Chen Director Cairnhill Pharma |

| | | |
|----------------|--|--|
| 4.15 pm | Commercialisation strategies for pharmaceutical products <ul style="list-style-type: none">• Regulatory activities in the context of commercialization and ensuring regulatory compliance in tech transfer• Assessing the commercial potential of innovations and inventions• Case examples | Mr. Andy Li NUS Enterprise National University of Singapore |
| 5.20 pm | Debrief and Announcements | CoRE Education Team |
| 5.30pm | End of Day 1 | |

Day 2 – 10 September 2024, Tue

| | Topic | Speaker/ Organisation |
|--|---|--|
| Session 3: Ensuring Quality, Safety and Efficacy of Pharmaceutical Products | | |
| 8.30 am | Overview of Chemistry, Manufacturing and Controls <ul style="list-style-type: none"> • Concept of pharmaceutical quality (PQ/CMC) • Importance and impact of pharmaceutical quality on patient safety • Pharmaceutical quality initiatives • Key regulatory guidelines and requirements • General practices in the industry providing quality assurance | Dr Rathi Saravanan Lead Education Associate CoRE Duke-NUS Medical School |
| 9.30 am | Manufacturing of pharmaceutical products <ul style="list-style-type: none"> • Introduction to regulatory control on quality • Introduction to ICH CTD Module 3 Quality section | Dr Sannie Chong Senior Director, APAC Regulatory Policy MSD |
| 10.30 am | Refreshment Break | |
| 10.45 am | Good Manufacturing Practices (GMP): Main Concepts <ul style="list-style-type: none"> • Failures in GMP • GMP history • Basic GMP requirements including definition and quality management | Dr Smitha Kenchath Consultant Seer Pharma (Singapore) Pte Ltd |
| 11.30 am | Overview of non-clinical requirements for pharmaceuticals <ul style="list-style-type: none"> • Types of nonclinical studies • Data for FIH studies | Adj Assoc/Prof Cynthia Sung CoRE Duke-NUS Medical School |
| 12.30 pm | Lunch | |
| 1.30 pm | Overview of Good Clinical Practice (GCP) requirements and clinical trial application (CTA) for pharmaceuticals <ul style="list-style-type: none"> • Principles of GCP • Key GCP guidelines (WHO/ICH/HSA) • CTA vs CTN | Dr Yvanka Gilliam Head of Clinical Alliances Singapore Clinical Research Institute (SCRI) |
| 2.00 pm | Overview of pharmaceuticals clinical development <ul style="list-style-type: none"> • Phases of Clinical Trials • Design of CT: inclusion exclusion criteria, endpoints | Dr Yvanka Gilliam Head of Clinical Alliances Singapore Clinical Research Institute (SCRI) |
| 3.00 pm | Refreshment Break | |
| 3.15 pm | Practicum I Clinical development of pharmaceuticals | Expert Faculty: Dr Yvanka Gilliam |
| 5.20 pm | Debrief and Announcements | CoRE Education Team |
| 5.30 pm | End of Day 2 | |

Day 3 – 11 September 2024, Wed

| | Topic | Speaker/ Organisation |
|--|---|--|
| 8.30 am | Individual and Group assessment I | |
| Session 4: Regulatory Processes for Pharmaceutical Products | | |
| 9.30 am | Market authorisation application (Pharmaceutical Products) <ul style="list-style-type: none"> Requirements for MAA submission and review in select countries ICH CTD submission requirements | Asst/Prof James Leong Head Pharmaceutical Regulatory Science Programme CoRE, Duke-NUS Medical School |
| 10.30 am | Refreshment Break | |
| 10.45 am | Regulatory requirements for regulatory decision making: Benefit-risk analysis <ul style="list-style-type: none"> Benefit-risk assessment for regulatory decision making | Asst/Prof James Leong CoRE, Duke-NUS Medical School |
| 12.00 pm | Lunch | |
| 1.00 pm | Practicum II Benefit-Risk Assessment of Pharmaceutical Products | Expert Faculty: Asst/Prof James Leong |
| 3.30 pm | Refreshment Break | |
| 3.45 pm | Good Submission Practices (GSubP) in supporting efficient therapeutics registration in ASEAN | Dr Sannie Chong Senior Director, APAC Regulatory Policy MSD |
| 4.30 pm | Good Review Practices (GRevP) and Regulatory cooperation <ul style="list-style-type: none"> WHO GRevP guideline Principles of a Good Review Managing the Review | Asst/Prof James Leong CoRE Duke-NUS Medical School |
| 5.20 pm | Debrief and Announcements | CoRE Education Team |
| 5.30pm | End of Day 3 | |

Day 4 – 12 September 2024, Thurs

| | Topic | Speaker/ Organisation |
|--|--|--|
| Session 5: Post-approval processes and product lifecycle management | | |
| 8.30 am | Managing post- approval quality changes <ul style="list-style-type: none"> • Risk based approach to post-approval changes • Reliance practices in post-approval CMC changes | Dr. Jeremy Shonberg Regional Senior Regulatory Scientist TGA Australia |
| 9.30 am | GMP compliance, audit and inspections | Dr Smitha Kenchath Consultant Seer Pharma (Singapore) Pte Ltd |
| 10.30 am | Refreshment Break | |
| 10.45 am | Total Product Lifecycle (TPLC) management | Asst/Prof James Leong CoRE Duke-NUS Medical School |
| 12.00 pm | Lunch | |
| 1.00 pm | Global trends in pharmacovigilance | Asst. Prof Tan-Koi Wei Chuen Assistant Professor, Advisory Lead CoRE Duke-NUS Medical School |
| 1.45 pm | Overview of pharmacovigilance for pharmaceutical products <ul style="list-style-type: none"> • Introduction to pharmacovigilance • Appreciation of the pharmacovigilance framework • Risk management plans and post-marketing activities | Dr Han Phey Yen Regulatory Consultant Vigilance & Compliance Branch Health Sciences Authority, Singapore |
| 2.30 pm | Practicum III Risk management plans for pharmaceutical products | Expert Faculty: Dr Han Phey Yen |
| 3.00 pm | Refreshment Break | |
| 3.15 pm | Practicum III Continued and Discussions | |
| 5.30pm | End of Day 4 | |

Day 5 – 13 September 2024, Fri

| | Topic | Speaker/ Organisation |
|---|--|--|
| 9.00 am | End-of-Module (EOM) Assessment | CoRE Education Team |
| 10.00 am | Refreshment Break | |
| 10.15 am | Review of EOM Questions | CoRE Education Team |
| Session 6: Trends in Health Products Development and Regulations | | |
| 11.00 am | Introduction to Precision Health and Medicine <ul style="list-style-type: none"> Overview of landscape National and Regional programs in Precision Medicine | Valerie Mbella Director Global Regulatory Affairs Diagnostics, Johnson & Johnson Innovative Medicine |
| 12.00 pm | Development and use of standards in supporting product development | Dr. Fan / Siow Kay CoRE SDO |
| 11.30 am | Patient engagement, Coalition to Accelerate Patient Engagement in Asia-Pacific (CAPE) <ul style="list-style-type: none"> Importance of patient involvement Patient engagement in product lifecycle Real world examples | Dr Khoo Yoong Khean Scientific Officer Global Health Policy CoRE Duke-NUS Medical School |
| 12.00 pm | Lunch | |
| 1.00 pm | Gallery Walk | CoRE Education Team |
| 3.00 pm | Introduction to Healthcare Services Regulation <ul style="list-style-type: none"> Trending areas in healthcare landscape Service models and technologies in Gene therapies | Asst. Prof. Kavitha Palaniappan Assistant Professor, Lead, Healthcare Services Regulation Group (HRG) CoRE Duke-NUS Medical School |
| 3.45 pm | Break | |
| 4.00 pm | Reflection and Peer Sharing | Dr. Rathi Saravanan CoRE |
| 5.15 pm | Graduate Certificate Workshop Conclusion | Prof Silke Vogel Deputy Director, CoRE Senior Associate Dean Graduate Studies Duke-NUS Medical School |
| 5.30pm | End of Workshop | |